DK3201234T3 - Antistof der binder en lineær epitop af human p53 og diagnostiske anvendelser deraf - Google Patents
Antistof der binder en lineær epitop af human p53 og diagnostiske anvendelser deraf Download PDFInfo
- Publication number
- DK3201234T3 DK3201234T3 DK15767529.9T DK15767529T DK3201234T3 DK 3201234 T3 DK3201234 T3 DK 3201234T3 DK 15767529 T DK15767529 T DK 15767529T DK 3201234 T3 DK3201234 T3 DK 3201234T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- human
- protein
- immunocomplex
- formation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7042—Aging, e.g. cellular aging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Claims (10)
1. Anti-humant p53-antistof, kendetegnet ved, at det binder til den lineære epitop af human p53 af sekvens RRTEEENLRKKGEPHH (SEQ ID NO: 1).
2. Antistof ifølge krav 1, der er et monoklonalt antistof.
3. Fremgangsmåde til fremstilling af et antistof ifølge et hvilket som helst af kravene 1 til 2, kendetegnet ved trinnene: (i) at immunisere et dyr, ikke-menneskeligt, med et immunogen omfattende et peptid af det humane p53-protein af sekvens CRTEEENLRKKGEPHH (SEQ ID NO: 2) eventuelt konjugeret med en bærer, hvor bæreren fortrinsvis er bovint serum albumin; og (ii) at isolere antistoffet opnået ved immunisering.
4. Immunoassay kit, omfattende mindst et antistof ifølge et hvilket som helst af kravene 1 til 2 og middel til at detektere bindingen af det nævnte antistof til humant p53-protein.
5. In vitro fremgangsmåde til at detektere en isoform af det humane p53-protein i en prøve, idet nævnte isoform er konformationelt ændret ved post-translationel modificering med hensyn til vildtype humant p53-protein, idet fremgangsmåden er kendetegnet ved, at prøven bringes i kontakt med mindst et antistof ifølge et hvilket som helst af kravene 1 til 2, og dannelsen af et immunokompleks mellem det humane p53-protein og antistoffet detekteres i prøven.
6. In vitro fremgangsmåde til at diagnosticere Alzheimers sygdom hos et individ, kendetegnet ved trinnene: (i) at bringe en biologisk prøve fra individet i kontakt med mindst et anti-humant p53-antistof ifølge et hvilket som helst af kravene 1 til 2 under betingelser der er egnede til dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof; og (ii) at detektere dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof, idet dannelsen af immunokomplekset er tegn på Alzheimers sygdom.
7. In vitro fremgangsmåde til at bestemme anlægget hos et individ påvirket af let kognitiv svækkelse for at udvikle Alzheimers sygdom, kendetegnet ved trinnene: (i) at bringe en biologisk prøve fra individet i kontakt med mindst et anti-humant p53-antistof ifølge et hvilket som helst af kravene 1 til 2 under betingelser der er egnede til dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof; og (ii) at detektere dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof, idet dannelsen af immunokomplekset er tegn på anlæg for at udvikle Alzheimers sygdom.
8. In vitro fremgangsmåde til at bestemme anlægget hos et individ for at udvikle kognitiv svaghed under ældning, kendetegnet ved trinnene: (i) at bringe en biologisk prøve fra individet i kontakt med mindst et anti-humant p53-antistof ifølge et hvilket som helst af kravene 1 til 2 under betingelser der er egnede for dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof; og (ii) at detektere dannelsen af et immunokompleks mellem det humane p53-protein og det mindst ene antistof, idet dannelsen af immunokomplekset er tegn på anlæg for at udvikle kognitiv svaghed under ældning.
9. In vitro fremgangsmåde ifølge et hvilket som helst af kravene 5 til 8, hvor den biologiske prøve er blod, plasma, serum, spyt, urin, neuronceller, blodceller eller andre celletyper.
10. In vitro fremgangsmåde ifølge et hvilket som helst af kravene 5 til 9, hvor detektionen udføres med immunpræcipitationsteknik, et immunassay, fortrinsvis ELISA eller RIA eller et immunfluorescensassay, Western Blot, FACS-analyse eller immuncytokemi-/immunhistokemiteknikker.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO20140776 | 2014-09-30 | ||
| PCT/EP2015/072094 WO2016050630A1 (en) | 2014-09-30 | 2015-09-25 | Antibody binding a linear epitope of human p53 and diagnostic applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3201234T3 true DK3201234T3 (da) | 2019-02-25 |
Family
ID=51904165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15767529.9T DK3201234T3 (da) | 2014-09-30 | 2015-09-25 | Antistof der binder en lineær epitop af human p53 og diagnostiske anvendelser deraf |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US10183990B2 (da) |
| EP (1) | EP3201234B1 (da) |
| JP (2) | JP6938372B2 (da) |
| CN (1) | CN107001453B (da) |
| CY (1) | CY1121169T1 (da) |
| DK (1) | DK3201234T3 (da) |
| ES (1) | ES2708556T3 (da) |
| HR (1) | HRP20190017T1 (da) |
| HU (1) | HUE042815T2 (da) |
| LT (1) | LT3201234T (da) |
| PL (1) | PL3201234T3 (da) |
| PT (1) | PT3201234T (da) |
| RS (1) | RS58244B1 (da) |
| RU (1) | RU2741795C2 (da) |
| SI (1) | SI3201234T1 (da) |
| TR (1) | TR201900550T4 (da) |
| WO (1) | WO2016050630A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3201234T (lt) | 2014-09-30 | 2019-03-12 | Diadem S.R.L. | Antikūnas, surišantis linijinį žmogaus p53 epitopą, ir jo panaudojimas diagnostikai |
| KR101885007B1 (ko) * | 2016-12-22 | 2018-08-31 | 가천대학교 산학협력단 | 인지기능장애의 진단 방법 및 키트 |
| EP3935394A1 (en) * | 2019-03-06 | 2022-01-12 | Diadem S.r.l. | P53 peptides as markers in the diagnosis and prognosis of alzheimer's disease |
| IT202000018544A1 (it) | 2020-07-30 | 2022-01-30 | Diadem S R L | Modificazioni post-traslazionali su p-53 quali marcatori nella diagnosi e prognosi di malattia neurodegenerativa |
| WO2024030982A2 (en) | 2022-08-02 | 2024-02-08 | Diadem Spa | Device for detection and prognostic assessment of neurodegenerative disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| AU722042B2 (en) * | 1995-11-30 | 2000-07-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the diagnosis and treatment of cancer |
| EP0929811A1 (en) * | 1996-10-07 | 1999-07-21 | Schering Corporation | ASSAY FOR THE DETECTION OF ANTIBODIES AGAINST p53 |
| CA2350597A1 (en) * | 1998-12-02 | 2000-06-08 | Barbara Ann Foster | Methods and compositions for restoring conformational stability of a protein of the p53 family |
| US20030180811A1 (en) * | 2002-03-11 | 2003-09-25 | Montero-Julian Felix A. | Immunoassays for beta2-microglobulin |
| KR100595494B1 (ko) * | 2003-02-24 | 2006-07-03 | (주) 디지탈바이오텍 | 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트 |
| ITMI20031709A1 (it) | 2003-09-05 | 2005-03-06 | Uni Degli Studi Brescia | Metodo per l'individuazione precoce della malattia di alzheimer. |
| US8101714B2 (en) * | 2004-02-18 | 2012-01-24 | The University Of Georgia Research Foundation, Inc. | Teleost derived antimicrobial polypeptides |
| US7833513B2 (en) * | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| CN101228187A (zh) * | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| US8703734B2 (en) * | 2005-12-12 | 2014-04-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nanoprobes for detection or modification of molecules |
| IL199534A (en) * | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| ES2496916T3 (es) * | 2007-05-31 | 2014-09-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas |
| CN101796070A (zh) * | 2007-05-31 | 2010-08-04 | 莱顿教学医院 | p53肽疫苗 |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| JP5812418B2 (ja) * | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| CN103837686A (zh) * | 2014-03-06 | 2014-06-04 | 上海北加生化试剂有限公司 | 一种检测人免疫球蛋白g4的试剂盒及其制备方法 |
| LT3201234T (lt) | 2014-09-30 | 2019-03-12 | Diadem S.R.L. | Antikūnas, surišantis linijinį žmogaus p53 epitopą, ir jo panaudojimas diagnostikai |
-
2015
- 2015-09-25 LT LTEP15767529.9T patent/LT3201234T/lt unknown
- 2015-09-25 PL PL15767529T patent/PL3201234T3/pl unknown
- 2015-09-25 JP JP2017516964A patent/JP6938372B2/ja active Active
- 2015-09-25 CN CN201580052913.0A patent/CN107001453B/zh active Active
- 2015-09-25 TR TR2019/00550T patent/TR201900550T4/tr unknown
- 2015-09-25 RU RU2017114626A patent/RU2741795C2/ru active
- 2015-09-25 EP EP15767529.9A patent/EP3201234B1/en active Active
- 2015-09-25 SI SI201530581T patent/SI3201234T1/sl unknown
- 2015-09-25 US US15/515,693 patent/US10183990B2/en active Active
- 2015-09-25 WO PCT/EP2015/072094 patent/WO2016050630A1/en active Application Filing
- 2015-09-25 RS RS20190070A patent/RS58244B1/sr unknown
- 2015-09-25 HU HUE15767529A patent/HUE042815T2/hu unknown
- 2015-09-25 DK DK15767529.9T patent/DK3201234T3/da active
- 2015-09-25 PT PT15767529T patent/PT3201234T/pt unknown
- 2015-09-25 ES ES15767529T patent/ES2708556T3/es active Active
-
2018
- 2018-12-10 US US16/214,455 patent/US10875908B2/en active Active
-
2019
- 2019-01-03 HR HRP20190017TT patent/HRP20190017T1/hr unknown
- 2019-01-22 CY CY20191100087T patent/CY1121169T1/el unknown
-
2020
- 2020-08-12 JP JP2020136359A patent/JP2020203895A/ja active Pending
- 2020-11-09 US US17/093,541 patent/US11208473B2/en active Active
- 2020-11-09 US US17/093,527 patent/US11203635B2/en active Active
-
2021
- 2021-11-17 US US17/528,946 patent/US11802148B2/en active Active
-
2023
- 2023-09-27 US US18/475,473 patent/US20240124565A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210070848A1 (en) | 2021-03-11 |
| ES2708556T3 (es) | 2019-04-10 |
| HRP20190017T1 (hr) | 2019-03-22 |
| EP3201234B1 (en) | 2018-11-07 |
| JP2017534595A (ja) | 2017-11-24 |
| RU2741795C2 (ru) | 2021-01-28 |
| PL3201234T3 (pl) | 2019-04-30 |
| RU2017114626A3 (da) | 2019-04-26 |
| US11802148B2 (en) | 2023-10-31 |
| US11203635B2 (en) | 2021-12-21 |
| WO2016050630A1 (en) | 2016-04-07 |
| US10875908B2 (en) | 2020-12-29 |
| US20180057572A1 (en) | 2018-03-01 |
| HUE042815T2 (hu) | 2019-07-29 |
| TR201900550T4 (tr) | 2019-02-21 |
| US20210061895A1 (en) | 2021-03-04 |
| LT3201234T (lt) | 2019-03-12 |
| US11208473B2 (en) | 2021-12-28 |
| EP3201234A1 (en) | 2017-08-09 |
| SI3201234T1 (sl) | 2019-03-29 |
| CN107001453A (zh) | 2017-08-01 |
| US20220064273A1 (en) | 2022-03-03 |
| RS58244B1 (sr) | 2019-03-29 |
| CY1121169T1 (el) | 2020-05-29 |
| JP2020203895A (ja) | 2020-12-24 |
| JP6938372B2 (ja) | 2021-09-22 |
| US20190194305A1 (en) | 2019-06-27 |
| CN107001453B (zh) | 2021-07-20 |
| US20240124565A1 (en) | 2024-04-18 |
| US10183990B2 (en) | 2019-01-22 |
| RU2017114626A (ru) | 2018-11-02 |
| PT3201234T (pt) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10875908B2 (en) | Antibody binding a linear epitope of human p53 and diagnostic applications thereof | |
| DK3054298T3 (da) | Fremgangsmåde til detektering af tumor i bugspytkirtlen | |
| US11614448B2 (en) | Compositions and methods for detecting prostate cancer | |
| KR20140100939A (ko) | 시트룰린화된 14-3-3 유래 항원 및 류마티스 관절염 진단에서의 이의 용도 | |
| US20150132744A1 (en) | Methods of detecting cells latently infected with hiv | |
| JP5484549B2 (ja) | 中皮腫診断キット | |
| US20220073611A1 (en) | Anti-nmda receptor antibodies and methods of use | |
| CN107110848B (zh) | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 | |
| JPWO2016121695A1 (ja) | 胆道癌の検出方法及び胆道癌検出用キット | |
| KR20130108324A (ko) | 대장직장암 마커에 대한 항체 | |
| Zhang et al. | Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu | |
| KR20230147034A (ko) | 항-pt217 타우 항체 | |
| US20120282633A1 (en) | Antibody specific to activated egfr | |
| WO2020100779A1 (ja) | ｐＳｅｒ４６－ＭＡＲＣＫＳに特異的に結合するモノクローナル抗体 | |
| CN114746755A (zh) | 测量蛋白酶介导的iv型胶原蛋白降解的新表位特异性测定 |